Loyal Funding & Investors

Loyal is developing drugs to extend dog lifespan; we aim to build the defining aging company. Loyal was founded in early 2020 and has raised over $50M from Khosla, First Round Capital, Collaborative Fund, Longevity Fund, Quiet Capital, BoxGroup, and more. Loyal is working on bringing to market the first drugs intended to extend lifespan (years of life) and healthspan (quality of life). We aspire to build a pharma brand people love around deeply technical products. While we are currently focusing on dog drugs, our ultimate aim is to take what we learn in dogs to leapfrog into human aging drugs, and build the company that catalyzes and captures the public’s excitement around aging therapeutics.